Form 4: AbbVie EVP Scott T. Reents Sells Shares on March 14, 2025

AbbVie's EVP and CFO, Scott T. Reents, sold 17,644 shares of common stock at an average price of $212.34 on March 14, 2025.

Summary

• On March 14, 2025, Scott T. Reents, the EVP and Chief Financial Officer of AbbVie Inc., sold 17,644 shares of AbbVie's common stock.
• The sale was executed at a weighted average price of $212.34 per share.
• The prices for individual transactions ranged from $212.27 to $212.49.
• Following the transaction, Reents directly owns 11,577 shares of AbbVie common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's performance. However, large or frequent sales can sometimes be viewed with concern by investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options and grants, leading to periodic sales.
• Comparing Reents' transactions to those of other CFOs in the pharmaceutical industry would provide a better understanding of whether this sale is typical.
• Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also have executives who periodically sell shares, and comparing the volume and frequency of those sales could be informative.

Stakeholder Impact

• The sale of shares by a high-ranking executive could potentially cause short-term uncertainty among shareholders.
• However, unless the sale is indicative of a larger trend or concern, the impact is likely to be minimal.

Key Dates